Medicus Pharma Reports ~80% Overall Response Rate, 73% Clinical Clearance From Clinical Validation Of Phase 2 SkinJect Dataset

Medicus Pharma Ltd. (NASDAQ:MDCX) has reported independent clinical validation of its Phase 2 SkinJect dataset, showing an overall response rate of approximately 80% and a clinical clearance rate of 73%. The study, led by Dr. Babar Rao, also indicated 40% histological clearance and evidence of sustained biological activity over time. These results highlight the potential effectiveness of Medicus's therapeutic assets in dermatology.